Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Company's green tea extract Tegreen 97 will be studied as a source of anti-cancer catechins at Purdue School of Consumer and Family Sciences, San Francisco-based Pharmanex announces. The study will "define whether a consistent level of EGCg and related catechins delivered to cancer cells will achieve an anti-cancer effect." The collaborative study builds upon research presented in 1998 at the American Society for Cell Biology annual meeting that showed "biologically relevant concentrations of epigallocatechin gallate (EGCg), the key catechin found naturally in green tea, effectively slowed the growth of tNOX, an overactive form of quinol oxidase (NOX)," Pharmanex explains. Earlier research suggests tNOX, "an enzyme suppressed on the surface of cancer cells, facilitates aggressive cell multiplication." Tegreen 97 contains 97% total pure polyphenols, of which 65% is catechins fractions and 40% of that is EGCg, according to labeling

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts